Last Updated: October 2026

What is a Clinical Trial Application (CTA), and how is it different from an IND?

A Clinical Trial Application (CTA) is the request a sponsor submits to a regulator outside the United States, such as in the EU, UK, or Canada, for permission to run a clinical trial. It plays the role an IND plays at the FDA. The core content is similar: protocol, investigator's brochure, quality data, and safety data. The main differences are that ethics review is usually part of the same process, and that each region has its own portal and timelines.

In this article

• What is a CTA?
• What goes into a CTA?
• How is a CTA different from an IND?
• How do CTAs work in the EU, UK, and Canada?
• What does the CTA submission process look like?
• What do you have to do after a CTA is approved?
• How Kivo supports CTA submissions, and how the options compare
• FAQ

What is a CTA?

A CTA is the formal application for authorisation to conduct a clinical trial in humans, submitted to a national or regional regulator outside the US. It gives the regulator, and usually an ethics committee, enough information to judge whether the trial is scientifically sound, ethically acceptable, and safe enough to start.

For biopharma and medtech teams running their first study outside the US, the CTA is the gate: no trial activity at sites in that country can begin until it is authorised. Getting the package right, and keeping it consistent across countries, is what keeps a global program on schedule.

What goes into a CTA?

Requirements vary by region, but most CTAs are built from the same core documents. Many of them are the same documents you would use for an IND.

• Cover letter and application form: sponsor, trial, product, and site details, plus any regional administrative forms.
• Clinical protocol: objectives, design, methodology, statistics, and participant protections.
• Investigator's brochure (IB): a summary of the nonclinical and clinical data on the investigational product so far.
• Quality (CMC) information: how the investigational product is manufactured, characterised, and controlled. In the EU this is the investigational medicinal product dossier (IMPD).
• Participant-facing documents: informed consent forms and recruitment materials, which ethics reviewers assess.
• Site and investigator information: evidence that sites and investigators are suitable, where the region requires it.

The most common cause of questions from regulators is inconsistency: a dose, population, or manufacturing detail that reads one way in the protocol and another in the IB or quality dossier. Keeping one controlled version of each document, and reusing it across countries, prevents most of these.

How is a CTA different from an IND?

A CTA and an IND both authorise human trials, but they work differently in four ways.

The practical result: a package built for the FDA rarely works unchanged elsewhere. Planning for regional forms, ethics documents, and local language requirements early saves rework later.

How do CTAs work in the EU, UK, and Canada?

Each region has its own process, and two of the three have changed in the last few years.

European Union

The EU Clinical Trials Regulation (EU) No 536/2014 has applied since 31 January 2022, replacing the Clinical Trials Directive. Since 31 January 2023, all new clinical trial applications must be submitted through the Clinical Trials Information System (CTIS), and since 31 January 2025, trials authorised under the old Directive that are still running must comply with the Regulation. One application covers every member state where the trial will run: one reporting member state leads the assessment of the scientific and quality content (Part I), and each member state assesses its national and ethics aspects (Part II). For more on CTIS, see Understanding CTIS Guidelines for EU Clinical Studies.

United Kingdom

The UK's Medicines for Human Use (Clinical Trials) (Amendment) Regulations 2025 came into force on 28 April 2026. Applications still go through a combined review: the MHRA and a research ethics committee review in parallel, through IRAS, and the sponsor gets a single UK decision. Under the new rules, the MHRA confirms validation within 7 calendar days and issues an initial decision within 30 calendar days of validation (120 days if an expert committee is consulted). Lower-risk "notifiable" trials receive automatic MHRA authorisation, confirmed within 14 calendar days of validation, while ethics review follows the usual timeline.

Canada

Health Canada reviews CTAs for drugs on a 30-day default basis: a trial may proceed if Health Canada has not objected within 30 days of receiving a complete application. Research ethics board approval is still required at each site before the trial starts there.

Other regions, including Japan and Australia, run their own schemes. Check each regulator's current guidance before you plan a timeline around it.

What does the CTA submission process look like?

Most CTAs follow the same four stages, whatever the country.

1. Pre-submission advice. Scientific advice meetings with the regulator clarify expectations for the product, design, and documents before you file, and are often worth it for a first-in-human or first-ex-US trial.
2. Package assembly. Assemble the protocol, IB, quality dossier, ethics documents, and regional forms, and reconcile them against each other.
3. Submission and validation. File through the regional portal. The regulator checks the package is complete before the review clock starts.
4. Review and requests for information. Regulator and ethics review run in parallel or in sequence. Fast, consistent answers to requests for information are the biggest controllable factor in timelines.

The pitfalls that cause most delays are predictable: inconsistent data across the protocol, IB, and quality sections; missing country-specific forms; scattered correspondence with several regulators and ethics bodies; and underestimating the lead time to coordinate sites across countries.

What do you have to do after a CTA is approved?

Authorisation starts a set of ongoing obligations that last until the end-of-trial report.

• Substantial modifications: significant changes to the protocol, product, or trial conduct must be submitted and approved before they are implemented.
• Safety reporting: suspected unexpected serious adverse reactions (SUSARs) must be reported within strict deadlines, along with periodic safety reports such as the annual development safety update report (DSUR).
• Notifications and reports: start of trial, end of trial, and results summaries, on each region's timelines.
• Inspection readiness: the trial master file must show the trial was run as authorised. See Why Sponsors Shouldn't Leave the TMF with Their CRO.

Tracking these across several countries is a correspondence and commitment problem as much as a document problem, which is where most teams' spreadsheets start to break.

How Kivo supports CTA submissions, and how the options compare

Kivo is a unified platform for clinical-stage biotech teams, with regulatory (RIM), clinical (eTMF), and quality (QMS) modules on one validated document management system. For a CTA, that means the protocol, IB, and quality documents are controlled once and reused across countries without copies drifting apart. Kivo RIM provides 450+ pre-formatted ICH templates, submission structures, and tracking of regulator correspondence and commitments, and Kivo eTMF keeps the trial master file aligned with what was authorised. Every edit and approval is captured in an automatic audit trail, with Kivo's native Part 11-compliant e-signature included. Kivo is rated 4.9/5 on G2 and is used by 200+ sponsor, consultant, and CRO teams.

Several vendors offer regulatory information management that supports clinical trial applications. The table below summarises Kivo and three alternatives at a category level.

This table is not an independent ranking. It does not assess implementation quality, market share, or fit for any particular organisation, and capabilities change, so confirm details with each vendor and validate against your own requirements.

FAQ

Is a CTA the same as an IND?

They serve the same purpose, authorising human trials, but in different places. An IND is filed with the FDA and goes into effect after 30 days unless the FDA places a clinical hold. A CTA is filed with a regulator outside the US, usually alongside ethics review, and follows that region's own process.

How long does CTA approval take?

It depends on the region. In the UK, the initial decision is due within 30 calendar days of validation, and Health Canada works on a 30-day default. EU timelines run under the Clinical Trials Regulation and can stretch when member states raise questions, so plan for requests for information.

Do I need a separate CTA for each EU country?

No. Under the EU Clinical Trials Regulation, one application submitted through CTIS covers all the member states where the trial will run. One reporting member state leads the scientific assessment, and each country reviews its own national and ethics aspects.

What changed for UK clinical trials in 2026?

New UK clinical trials regulations came into force on 28 April 2026. Combined MHRA and ethics review through IRAS continues, with set decision timelines, and lower-risk "notifiable" trials receive automatic MHRA authorisation, confirmed within 14 calendar days of validation.

Can I reuse my IND documents for a CTA?

Largely, yes. The protocol, investigator's brochure, and quality and nonclinical data can usually be reused, but expect regional forms, an EU-format quality dossier, ethics and consent documents, and sometimes local-language materials on top.

References

1. EMA: Clinical Trials Regulation
2. MHRA: Medicines clinical trials collection
3. MHRA: Clinical trials for medicines, apply for approval in the UK
4. MHRA: Clinical trials for medicines, notifiable trials
5. Health Canada: Guidance for Clinical Trial Sponsors
6. 21 CFR 312.40: Requirements for an IND to go into effect